Two recent events have served to highlight the range of difficult questions raised by pharmaceuticals regulation. Last week, a man died in the French city of Rennes after a clinical trial of a painkiller went tragically wrong. In New York last month, Martin Shkreli, a former hedge fund manager, was arrested on securities fraud charges; Shkreli, who denies wrongdoing, won the sobriquet of “most hated man in America” after the company he controlled raised the price of the life-saving drug, Daraprim, from $13.50 a tablet to $750.
最近发生的两件事突显了药品监管方面的多个难题。1月中旬，法国雷恩市(Rennes)一场止痛药临床试验不幸出错，致一名男子死亡。去年12月，纽约前对冲基金经理马丁•史克雷利(Martin Shkreli)因涉嫌证券欺诈被捕，不过他否认自己有违法行为。此前史克雷利执掌的公司将救命药达拉匹林(Daraprim)的售价从13.5美元一片抬高到750美元一片，令他荣获“全美最可恨的人”封号。
您已阅读15%（724字），剩余85%（4155字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。